Efficacy and safety of oliceridine versus remifentanil for analgesia in mechanically ventilated critically ill adults (CO-ROAM): a multicenter, assessor-blinded, non-inferiority randomized controlled trial
Intensive Care Medicine · 10.11.2026
DOI: 10.1007/s00134-026-08643-8 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Intensive Care Medicine, online erschienen am 10.11.2026. Verfasst von Sen Lu und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science …. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Hospital Fund of Sichuan Provincial People's Hospital.
Abstract (Originalsprache)
PURPOSE: Remifentanil provides effective analgesia during invasive mechanical ventilation (IMV), but its utility is limited by opioid-related adverse events. Oliceridine, a G protein-biased μ-opioid receptor agonist, may decouple analgesia from these effects, but lacks evidence in critically ill patients. METHODS: This multicentre, assessor- and patient-blinded, non-inferiority randomised controlled trial was conducted across 19 intensive care units (ICUs) in China. Adults receiving IMV were randomised 1:1 to oliceridine or remifentanil, titrated to a Critical-Care Pain Observation Tool score below 3. The primary endpoint was time in target analgesic range (TTR; non-inferiority margin -10%). RESULTS: Of 307 randomised patients, 304 comprised the modified intention-to-treat population (151 oliceridine, 153 remifentanil). Median TTR was 96.0% versus 92.3% (absolute difference 3.7%, 95% CI -0.3-5.7%). Oliceridine was associated with fewer mild-to-moderate adverse drug reactions (ADRs), occurring at 15.9 versus 22.2 events per 100 patient-days (IRR 0.72, 95% CI 0.52-1.00, P = 0.049), and a lower rate of respiratory depression during the study period (0% vs. 4.6%, P = 0.015). Post-extubation respiratory depression (0% vs. 7.9%, P = 0.005) and analgesic-sedation costs were both lower with oliceridine. IMV duration, ICU stay, and 28-day mortality did not differ. Subgroup analyses identified a nominal ADR benefit in patients with Acute Physiology and Chronic Health Evaluation II > 17 and a larger nominal TTR difference in those without acute respiratory distress syndrome. CONCLUSION: Oliceridine provides non-inferior analgesia to remifentanil with a more favourable respiratory safety profile and lower costs in critically ill adults. TRIAL REGISTRATION: ClinicalTrials.gov NCT06454292 (registered June 11, 2024).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Critical Care Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
- Department of Critical Care Medicine, Fushun People's Hospital, Zigong, China.
- Department of Critical Care Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
- Department of Critical Care Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
- Department of Critical Care Medicine, The Third Hospital of Mianyang, Mianyang, China.
- Department of Critical Care Medicine, Sichuan University affiliated Chengdu Second People's Hospital, Chengdu Second People's Hospital, Chengdu, China.
Förderung
- the Hospital Fund of Sichuan Provincial People's Hospital
Zitieren
APA
Lu, S., Luo, J. C., Li, Q., Lei, X. Y., Ding, X. F., Dong, Q. L., Hu, Q. H., Zhu, W. T., Zhang, X., Duan, L. L., Lv, S., Ran, Q. F., Ma, L., Guo, C., Dong, J. J., Yang, Y. Q., Xu, L., Yang, J., Wang, J., …, & Martin-Loeches, I. (2026). Efficacy and safety of oliceridine versus remifentanil for analgesia in mechanically ventilated critically ill adults (CO-ROAM): a multicenter, assessor-blinded, non-inferiority randomized controlled trial. Intensive Care Medicine. https://doi.org/10.1007/s00134-026-08643-8
Vancouver
Lu S, Luo JC, Li Q, Lei XY, Ding XF, Dong QL, et al. Efficacy and safety of oliceridine versus remifentanil for analgesia in mechanically ventilated critically ill adults (CO-ROAM): a multicenter, assessor-blinded, non-inferiority randomized controlled trial. Intensive Care Medicine. 2026. doi:10.1007/s00134-026-08643-8
BibTeX
@article{Lu2026,
author = {Lu, Sen and Luo, Jing-Chao and Li, Qiang and Lei, Xian-Ying and Ding, Xue-Feng and Dong, Qiong-Lan and Hu, Qiong-Hua and Zhu, Wen-Tuo and Zhang, Xue and Duan, Li-Li and Lv, Sheng and Ran, Qi-Fang and Ma, Li and Guo, Chuan and Dong, Jian-Jun and Yang, Yu-Qi and Xu, Li and Yang, Jin and Wang, Jun and Qiu, Li-Fei and Jing, Ben-Cai and Jia, Feng-Juan and Zhang, Li and Tang, Qi-Bing and Ibarra-Estrada, Miguel and Luo, Ming-Hao and Pan, Chun and Huang, Xiao-Bo and Martin-Loeches, Ignacio},
title = {Efficacy and safety of oliceridine versus remifentanil for analgesia in mechanically ventilated critically ill adults (CO-ROAM): a multicenter, assessor-blinded, non-inferiority randomized controlled trial},
journal = {Intensive Care Medicine},
year = {2026},
doi = {10.1007/s00134-026-08643-8}
}
EUVIMED